medigraphic.com
ISSN 1561-2988 (Print)

2019, Number 3

<< Back Next >>

Rev Cubana Farm 2019; 52 (3)

Prediction of bleeding probabilities by the use of warfarin sodium

Elías SR, Elias AKS, Pérez CJ

Language: Spanish
References: 15
Page: 1-13
PDF size: 605.19 Kb.


ABSTRACT

Introduction: During the therapeutic anticoagulation is important to maintain vigilance over the patient because there might occur bleedings associated to the therapy.
Objective: To design a tool to predict the bleeding probabilities by the use of warfarin sodium.
Methods: An observational study was conducted in 50 patients treated with warfarin in "Dr. Agostinho Neto" Hospital, during the biennium 2016-2017. It was studied the age, sex, motive of the prescription and dose of warfarin; also the compliance and medical treatment´s control, the use of drugs that interfere with the action of warfarin and the comorbidity. It was developed and validated a scale to predict the bleeding probabilities by the use of warfarin.
Results: The predictive scale designed showed a high level of accuracy, because it was possible to accurately predict the risk of bleeding by the use of warfarin sodium.
Conclusions: The scale developed allowed to do a more objective prediction of the anticoagulant effect of warfarin sodium. So that is configured in a scientific methodological instrument for clinical monitoring of patients treated with warfarin, which boosts the quality of the medical attention.


REFERENCES

  1. Belmar VL, de Francisco ALM, Bada SJ, Galván EL, Fernández FG. Nuevos anticoagulantes orales en pacientes con enfermedad renal crónica. Nefrología. 2017;37(3):244-252. Disponible en: http://dx.doi.org/10.1016/j.nefro.2016.08.006

  2. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383(9921):955- 62.25. Disponible en: http://dx.doi.org/10.1016/S0140-6736(13)62343-0

  3. Andreu CJM, Pastor PFJ, Puche CM, Mateo MA, García AA, Flores BPJ, et al. Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardiaca aguda reciente Rev Esp Cardiol. 2016;69(2):134-140. Disponible en: http://dx.doi.org/10.1016/j.recesp.2015.06.022

  4. Jaramillo SRG, Jiménez GJD, Pinilla RAE. Uso de los anticoagulantes orales directos en la práctica clínica. Rev. Fac. Med. 2016;64(2):295-308. Disponible en: http://dx.doi.org/10.15446/ revfacmed.v64n2.49963

  5. Morimoto T, Crawford B, Wada K, Ueda S. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies. J Cardiol. 2015;66(6):466-74. Disponible en: http://dx.doi.org/10.1016/j.jjcc.2015.05.018

  6. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with non valvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014;113(3):485-90. Disponible en: http://dx.doi.org/10.1016/j.amjcard.2013.10.035

  7. Fu W, Guo H, Guo J, Lin K, Wang H, Zhang Y, et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. J Cardiovasc Med (Hagerstown). 2014 [acceso 26/07/2018];15(12):873-879. Disponible en: http://dx.doi.org/10.2459/JCM.0000000000000206

  8. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. Anovel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The EuroHeart Survey. Chest. 2010;138(5):1093-100. Disponible en: https://dx.doi.org/10.1378/chest.10-0134

  9. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320-8. Disponible en: http://dx.doi.org/10.1111/jth.12485

  10. Leal HM, Marín F. Uso del tratamiento antitrombótico en pacientes con fibrilación auricular en atención primaria. Rev Esp Cardiol. 2014 [acceso 08/08/2017];67(5):419-423. Disponible en: http://www.revespcardiol.org/es/uso-del-tratamiento-antitromboticopacientes/ articulo/90302532/

  11. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007 [acceso 26/07/2018];147(8):590-2. Disponible en: http://dx.doi.org/10.7326/0003-4819-147-8-200710160-00018

  12. García FR, Cuellar GL. Actualidades en trombosis. Med Int Méx. 2016 [acceso 26/07/2018];32(1):103-114. Disponible en: http://www.medigraphic.com/pdfs/medintmex/mim-2016/mim161m.pdf

  13. Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014 [acceso 26/07/2018];3(3):e000515. Disponible en: http://dx.doi.org/10.1161/JAHA.113.000515

  14. Barrios V, Escobar C, Calderón A, Rodríguez RG, Llisterri JL. Uso del tratamiento antitrombótico según la escala CHA 2DS2-VASc en los pacientes con fibrilación auricular. Rev Esp Cardiol. 2014 [acceso 26/07/2018];67(5):150-151. Disponible en: http://www.revespcardiol.org/es/pdf/%2090267583/S300/

  15. Ferreira J, Mirco A. Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. Rev Port Cardiol. 2015 [acceso 08/08/2018];34(4):179-91. Disponible en: http://refhub.elsevier.com/S0211-6995(16)30140- 0/sbref0450




2020     |     www.medigraphic.com